GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (NAS:LIFE) » Definitions » Shiller PE Ratio

aTyr Pharma (aTyr Pharma) Shiller PE Ratio

: (As of Today)
View and export this data going back to 2015. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation


aTyr Pharma Shiller PE Ratio Historical Data

The historical data trend for aTyr Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

aTyr Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

aTyr Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, aTyr Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


aTyr Pharma Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, aTyr Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's Shiller PE Ratio falls into.



aTyr Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

aTyr Pharma's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, aTyr Pharma's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.25/129.4194*129.4194
=-0.250

Current CPI (Dec. 2023) = 129.4194.

aTyr Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -8.660 99.695 -11.242
201406 -7.960 100.560 -10.244
201409 -9.409 100.428 -12.125
201412 -8.392 99.070 -10.963
201503 -5.632 99.621 -7.317
201506 -10.360 100.684 -13.317
201509 -6.720 100.392 -8.663
201512 -9.800 99.792 -12.709
201603 -9.520 100.470 -12.263
201606 -9.100 101.688 -11.582
201609 -8.120 101.861 -10.317
201612 -7.420 101.863 -9.427
201703 -7.840 102.862 -9.864
201706 -7.140 103.349 -8.941
201709 -6.020 104.136 -7.482
201712 -5.460 104.011 -6.794
201803 -5.040 105.290 -6.195
201806 -4.880 106.317 -5.940
201809 -3.330 106.507 -4.046
201812 -2.940 105.998 -3.590
201903 -2.540 107.251 -3.065
201906 -1.800 108.070 -2.156
201909 -1.470 108.329 -1.756
201912 -1.540 108.420 -1.838
202003 0.250 108.902 0.297
202006 -0.690 108.767 -0.821
202009 -0.680 109.815 -0.801
202012 -0.470 109.897 -0.553
202103 -0.510 111.754 -0.591
202106 -0.640 114.631 -0.723
202109 -0.420 115.734 -0.470
202112 -0.310 117.630 -0.341
202203 -0.440 121.301 -0.469
202206 -0.440 125.017 -0.455
202209 -0.460 125.227 -0.475
202212 -0.260 125.222 -0.269
202303 -0.290 127.348 -0.295
202306 -0.220 128.729 -0.221
202309 -0.200 129.860 -0.199
202312 -0.250 129.419 -0.250

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


aTyr Pharma  (NAS:LIFE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


aTyr Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of aTyr Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


aTyr Pharma (aTyr Pharma) Business Description

Traded in Other Exchanges
Address
10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Executives
Sanjay Shukla officer: Chief Medical Officer C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO CA 92121
Paul Schimmel director 88 SIDNEY ST, CAMBRIDGE MA 02139
Jill Marie Broadfoot officer: Chief Financial Officer 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Sara Zaknoen director C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121
John K Clarke director C/O CARDINAL HEALTH PARTNERS, 221 NASSAU STREET, PRINCETON NJ 08542
Nancy Krueger officer: See Remarks C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Svetlana Lucas director 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
John Mendlein director, officer: CEO and Executive Chairman
Ecor1 Capital Fund Qualified, L.p. 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ashraf Amanullah officer: Vice President, Manufacturing C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
John T Blake officer: Vice President, Finance C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342
Timothy P Coughlin director 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Jeffrey S. Hatfield director 11080 ROSELLE STREET, SAN DIEGO CA 92121
David John King officer: See Remarks 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121

aTyr Pharma (aTyr Pharma) Headlines

From GuruFocus

aTyr Pharma Announces Commencement of Public Offering of Common Stock

By sperokesalga sperokesalga 02-08-2023

aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference

By sperokesalga sperokesalga 05-25-2023

aTyr Pharma Announces Pricing of Public Offering of Common Stock

By sperokesalga sperokesalga 02-09-2023